Glenmark to Commercialise BeiGene’s Oncology Medicines in India

Glenmark Pharmaceuticals on Tuesday said its subsidiary Glenmark Speciality S.A. (Glenmark) signed an exclusive marketing and distribution agreement with BeiGene. Glenmark will register and commercialise BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India. 

Key Takeaways from Glenmark Pharmaceuticals:

• Glenmark signed an exclusive marketing and distribution agreement with BeiGene.
• Glenmark will register and commercialise BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India. 
• Glenmark will be responsible for locally required development, registration, and distribution.

Tislelizumab is a novel anti-PD-1 monoclonal antibody approved by NMPA, EMA and FDA for treating advanced or metastatic oesophagal squamous cell carcinoma and various types of cancers as well. While Zanubrutinib, a BTK inhibitor is used in the treatment of certain hematological malignancies.

Under this collaboration, Glenmark will be responsible for locally required development, registration, and distribution leveraging BeiGene's innovative oncology medicines for cancer patients across India.

The partnership will help many low-and middle-income countries, including India, overcome the burden of cancer. Statistically, India has the third highest number of cancer cases worldwide. Currently, cancer claims approximately 900,000 lives annually in India.

About Glenmark Pharmaceuticals Limited:

Glenmark Pharmaceuticals Limited is a research-led, global pharmaceutical company with a presence across branded, generic, and OTC segments. The company focuses on therapeutic areas of respiratory, dermatology, and oncology. It has 11 world-class manufacturing facilities across four continents, and operations in over 80 countries. 

Read More About Glenmark Pharmaceuticals Limited Share Price Here!